Our team integrates vision with next-generation science and technology
to enable new options for tough-to-treat cancers.
Vivacitas Oncology is a private clinical stage biopharmaceutical company focused on tough-to-treat cancers resistant to current treatment modalities.
Vivacitas’ lead candidate ( AR-67) is a novel lipophilic compound targeting improved efficacy and tolerability.
Vivacitas maintains intellectual property defining systems and methods for camptothecin analog synthesis.
The team shares a common belief that our primary focus and responsibilities are to patients with cancer and their families.
Vivacitas is supported by a highly respected team of medical advisors and researchers as we assess, develop, and transform select therapies to unlock their treatment potential.
Vivacitas lead compound, AR-67, is a synthetic, highly lipophilic derivative of the natural alkaloid camptothecin, with potential antineoplastic and radiosensitizing activities (Bom et al, 2000; Chen et al, 2005). AR-67 has improved physicochemical properties compared to other camptothecin-derived therapies.
Clinical data from Phase I and II trials in multiple tumor types demonstrate AR-67’s treatment potential. Phase II data in recurrent glioblastoma (brain cancer) showed potential of progression free survival of 6-29 months and less severe side effects (e.g. Grade 4 diarrhea).
AR-67 received Orphan Drug Designation from the FDA for Glioblastoma.
Our scientists, clinicians, industry executives, and medical advisors came together with a shared mission: to improve the lives of cancer patients by gaining power over the disease.
Each is an accomplished professional and their combined expertise is a force de rigueur in combating the hardest to treat cancers.
Vivacitas applies integrity, clarity, tenacity, collaboration, and teamwork to pursue superior results in the lives of cancer patients.
Vivacitas is seeking investors and partners to enable continued development and potential registration of AR-67 in multiple solid tumors. Successful Phase II study results will potentially lead to a strategic exit.
Additional details on investment opportunities are available upon request.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Eget rhoncus viverra tristique aliq uam et praesent adipiscing turpis auris.
WALNUT CREEK, CALIFORNIA, US, November 30, 2021 – Vivacitas Oncology, Inc. (“Vivacitas” or the “Company”) is pleased to announce the addition of Mark Suseck as new Director and Chief Executive Officer and Frank D. Heuszel as Director.
Walnut Creek, CA, USA, November 22, 2021, Vivacitas Oncology, Inc., a privately-held oncology company focused on tough–to–treat cancers, will present its lead development candidate, AR-67, at this year’s 5th Meridian Clinical Trials (MCT) conference November 22-23, 2021 via their online platform.
Walnut Creek, CA, USA, and London, UK, November 18, 2021, Vivacitas Oncology, a privately-held oncology company focused on tough–to–treat cancers, and Image Analysis Group (IAG), a premier image analysis company and developer of the proprietary Artificial Intelligence (AI)-assisted Dynamika™ platform will present a poster at this year’s annual Society of Neuro-Oncology (SNO) conference November 18-21, 2021 in Boston, MA.
1. Novel silatecan displays high lipophilicity, improved blood stability and potent
anticancer activity. Bom D, et al J Med Chem 2000; 43:3970-3980
2. Silatecan DB-67 is a novel DNA Topo-1 targeted radiation sensitizer: Chen AY. Mol
Cancer Ther 2005; 4(2): 317-24.
3. Phase I study publication: Arnold SM, et al. Clin Cancer Res. 2010;6:673-680
4. Phase II study publication (abstract): Kumthekar P, et al. SNO 2019. Poster ACTR-40,
published in Neuro-Oncology(https://academic.oup.com/neuro-oncology)
5. Ubiquitin-dependent Destruction of Topoisomerase I Is
Stimulated by the Antitumor Drug Camptothecin*, Desai et al. The Journal of Biological Chemistry, Vol. 272, No. 39, Issue of September 26, pp. 24159–24164, 1997. https://www.jbc.org
6. Metabolic Pathways of the Camptothecin Analog AR-67, Horn et al. Drug Metabolism and Disposition, Vol. 39, No. 4, 37390/3672838, 2011. https://dmd.aspetjournals.org